Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Deciphering breast cancer: from biology to the clinic
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
Spatial biology of cancer evolution
The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …
driving forces of cancer development are mutation and selection of fitter clones. Cancer …
[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte–tumor cell crosstalk, local immunosuppression and tumor progression
Dissecting and understanding the cancer ecosystem, especially that around the tumor
margins, which have strong implications for tumor cell infiltration and invasion, are essential …
margins, which have strong implications for tumor cell infiltration and invasion, are essential …
Genomic–transcriptomic evolution in lung cancer and metastasis
Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion
and resistance to therapy. Here, using paired whole-exome and RNA sequencing data, we …
and resistance to therapy. Here, using paired whole-exome and RNA sequencing data, we …
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
J Wang, B Li, M Luo, J Huang, K Zhang… - Signal transduction and …, 2024 - nature.com
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression
F Lüönd, S Tiede, G Christofori - British journal of cancer, 2021 - nature.com
Heterogeneity within a tumour increases its ability to adapt to constantly changing
constraints, but adversely affects a patient's prognosis, therapy response and clinical …
constraints, but adversely affects a patient's prognosis, therapy response and clinical …
Intratumor heterogeneity: the rosetta stone of therapy resistance
Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …
into knowledge-based therapies directed against specific oncogenic signaling targets …
Genetic and non-genetic clonal diversity in cancer evolution
The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …
studies, has advanced our understanding of the evolutionary forces that shape cancer …